Market Summary
USD25.57-0.06
Market Closed-0.23%
SDGR Alerts
SDGR Stock Price
SDGR RSI Chart
SDGR Valuation
SDGR Price/Sales (Trailing)
SDGR Profitability
SDGR Fundamentals
SDGR Revenue
SDGR Earnings
Price Action
52 Week Range
15.8536.33
(Low)(High)
Last 7 days
-4.0%
Last 30 days
13.3%
Last 90 days
35.6%
Trailing 12 Months
-28.5%
SDGR Financial Health
SDGR Investor Care
Peers (Alternatives to Schrodinger)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABT | 171.9B | 43.7B | -4.52% | -15.68% | 24.79 | 3.94 | 1.34% | -1.95% |
IDXX | 40.2B | 3.4B | 1.94% | -10.16% | 59.26 | 11.95 | 4.73% | -8.83% |
CERN | 27.9B | - | 0.98% | 20.75% | 47.36 | 4.81 | - | - |
VEEV | 27.3B | 2.1B | 2.66% | -11.21% | 68.85 | 13.14 | 17.88% | -8.53% |
| MID-CAP | ||||||||
CHNG | 9.0B | 3.5B | 11.88% | 31.28% | -116.8 | 2.57 | 7.15% | -34.72% |
INSP | 7.2B | 407.9M | -5.66% | 0.14% | -160.52 | 17.66 | 74.75% | -6.75% |
LNTH | 5.6B | 935.1M | 39.79% | 59.89% | 199.63 | 5.99 | 119.91% | 139.38% |
TDOC | 4.1B | 2.4B | -14.85% | -63.89% | -0.3 | 1.7 | 18.41% | -3085.58% |
QDEL | 3.7B | - | -3.05% | -21.16% | 3.27 | 1.42 | - | - |
OMCL | 2.5B | 1.3B | 3.33% | -58.26% | 435.11 | 1.9 | 14.48% | -92.74% |
| SMALL-CAP | ||||||||
SDGR | 1.6B | 181.0M | 13.34% | -28.48% | -10.65 | 8.78 | 31.19% | -48.60% |
TRHC | 135.4M | 357.1M | -14.68% | -11.66% | -0.97 | 0.38 | 33.22% | -57.66% |
ICAD | 32.3M | 29.3M | -52.94% | -68.00% | -2.2 | 1.1 | -19.35% | -69.01% |
HTGM | 3.1M | 6.8M | -1.47% | 116.13% | -0.14 | 0.45 | -21.00% | -36.01% |
Financials for Schrodinger
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 6.3% | 180,955,000 | 170,282,000 | 163,152,000 | 154,467,000 | 137,931,000 |
| Gross Profit | 13.9% | 101,022,000 | 88,679,000 | 82,593,000 | 77,439,000 | 65,620,000 |
| Operating Expenses | 8.0% | 247,839,000 | 229,473,000 | 211,898,000 | 193,613,000 | 177,063,000 |
| S&GA Expenses | 12.5% | 30,642,000 | 27,235,000 | 25,630,000 | 23,582,000 | 22,150,000 |
| R&D Expenses | 8.0% | 126,372,000 | 116,975,000 | 107,309,000 | 97,278,000 | 90,904,000 |
| EBITDA | 2.4% | -144,782,000 | -148,369,000 | -144,248,000 | -131,909,000 | -97,961,000 |
| EBITDA Margin | 8.2% | -0.80 | -0.87 | -0.88 | -0.85 | -0.71 |
| Earnings Before Taxes | 2.0% | -149,126,000 | -152,223,000 | -147,576,000 | -134,838,000 | -100,808,000 |
| EBT Margin | 7.8% | -0.82 | -0.89 | -0.90 | -0.87 | -0.73 |
| Net Income | 2.3% | -149,186,000 | -152,691,000 | -147,845,000 | -135,141,000 | -100,393,000 |
| Net Income Margin | 8.1% | -0.82 | -0.90 | -0.91 | -0.87 | -0.73 |
| Free Cahsflow | -4.6% | -127,697,000 | -122,104,000 | -102,164,000 | -107,820,000 | -77,836,000 |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 4.0% | 689 | 662 | 688 | 720 | 756 |
| Current Assets | 1.9% | 534 | 524 | 557 | 586 | 625 |
| Cash Equivalents | -12.0% | 90.00 | 103 | 127 | 117 | 120 |
| Net PPE | 3.6% | 14.00 | 14.00 | 12.00 | 11.00 | 10.00 |
| Goodwill | 0% | 5.00 | 5.00 | 5.00 | 5.00 | - |
| Liabilities | 21.0% | 241 | 199 | 195 | 189 | 199 |
| Current Liabilities | 22.5% | 109 | 89.00 | 86.00 | 86.00 | 91.00 |
| Shareholder's Equity | -3.3% | 448 | 463 | 493 | 531 | 557 |
| Retained Earnings | -7.7% | -379 | -351 | -312 | -264 | -229 |
| Additional Paid-In Capital | 1.3% | 829 | 818 | 808 | 797 | 787 |
| Accumulated Depreciation | - | 12.00 | - | - | - | - |
| Shares Outstanding | -12.7% | 62.00 | 71.00 | 62.00 | 62.00 | 62.00 |
| Minority Interest | -8.3% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -4.5% | -119 | -114 | -94.75 | -99.47 | -70.67 |
| Share Based Compensation | 7.5% | 40.00 | 37.00 | 35.00 | 31.00 | 26.00 |
| Cashflow From Investing | 59.7% | 90.00 | 56.00 | 101 | 81.00 | -16.81 |
| Cashflow From Financing | -25.8% | 2.00 | 3.00 | 4.00 | 5.00 | 8.00 |
Risks for SDGR
What is the probability of a big loss on SDGR?
97.0%
Probability that Schrodinger stock will be more than 20% underwater in next one year
82.3%
Probability that Schrodinger stock will be more than 30% underwater in next one year.
81.7%
Probability that Schrodinger stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SDGR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Schrodinger was unfortunately bought at previous high price.
Drawdowns
Returns for SDGR
Cumulative Returns on SDGR
-14.8%
3-Year Cumulative Returns
Which funds bought or sold SDGR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | added | 54.16 | 4,528,520 | 34,050,500 | 0.04% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 83.00 | 1,000 | 3,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -130,762 | 387,238 | -% |
2023-02-24 | NATIXIS | reduced | -5.72 | -459,318 | 994,682 | 0.01% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -50,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -65.00 | 935 | -% |
2023-02-16 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | unchanged | - | -21,585 | 65,415 | -% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | -20,071 | 60,929 | -% |
2023-02-15 | Capital Impact Advisors, LLC | added | 74.1 | 115,733 | 279,733 | 0.27% |
2023-02-15 | JANE STREET GROUP, LLC | reduced | -69.23 | -1,537,980 | 460,017 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
SDGR Alerts
Schrodinger News
Schedule 13G FIlings of Schrodinger
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 8.25% | 5,120,349 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 6.4% | 3,956,805 | SC 13G | |
| Feb 09, 2022 | blackrock inc. | 5.0% | 3,057,148 | SC 13G/A | |
| Feb 04, 2022 | blackrock inc. | 5.1% | 3,123,673 | SC 13G | |
| Dec 01, 2021 | shaw david e | 3.9% | 2,401,777 | SC 13G/A | |
| Apr 26, 2021 | shaw david e | 17.2% | 9,662,606 | SC 13G/A | |
| Feb 12, 2021 | bill & melinda gates foundation trust | 23.2% | 16,145,857 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 6.76% | 3,805,264 | SC 13G | |
| Jan 19, 2021 | shaw david e | 17.2% | 9,662,606 | SC 13G | |
| Feb 10, 2020 | flynn james e | 0.52% | 250,000 | SC 13G |
SDGR Fair Value
Schrodinger fair value in different scenarios
The table shows the Fair Value estimates for Schrodinger for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 2.11 -91.75% | 2.58 -89.91% | 3.81 -85.10% | 5.52 -78.41% | 7.36 -71.22% |
| Current Inflation | 2.07 -91.90% | 2.50 -90.22% | 3.57 -86.04% | 5.05 -80.25% | 6.64 -74.03% |
| Very High Inflation | 2.03 -92.06% | 2.40 -90.61% | 3.29 -87.13% | 4.50 -82.40% | 5.79 -77.36% |
Historical Schrodinger Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Schrodinger
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Feb 28, 2023 | 8-K | Current Report | |
| Feb 28, 2023 | 10-K | Annual Report | |
| Feb 10, 2023 | SC 13G | Major Ownership Report | |
| Feb 10, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | 4 | Insider Trading | |
| Feb 10, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for SDGR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-02-09 | Abel Robert Lorne | acquired | - | - | 10,545 | see remarks |
2023-02-09 | Lorton Kenneth Patrick | acquired | - | - | 8,170 | evp & chief technology officer |
2023-02-09 | Herman Jenny | acquired | - | - | 8,000 | svp & controller |
2023-02-09 | Tran Yvonne | acquired | - | - | 7,590 | evp & chief legal officer |
2023-02-02 | Tran Yvonne | acquired | 74,990 | 2.99961 | 25,000 | evp & chief legal officer |
2023-02-02 | Tran Yvonne | sold | -681,380 | 27.2552 | -25,000 | evp & chief legal officer |
2023-01-04 | Farid Ramy | sold | -1,222,670 | 18.2799 | -66,886 | president & ceo |
2023-01-04 | Farid Ramy | acquired | 80,263 | 1.2 | 66,886 | president & ceo |
2022-08-11 | Thornberry Nancy | acquired | 57,024 | 11.52 | 4,950 | - |
2022-08-11 | Thornberry Nancy | sold | -173,250 | 35.00 | -4,950 | - |
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues: | |||
| Total revenues | $ 180,955 | $ 137,931 | $ 108,095 |
| Cost of revenues: | |||
| Total cost of revenues | 79,933 | 72,311 | 44,623 |
| Gross profit | 101,022 | 65,620 | 63,472 |
| Operating expenses: | |||
| Research and development | 126,372 | 90,904 | 64,695 |
| Sales and marketing | 30,642 | 22,150 | 17,795 |
| General and administrative | 90,825 | 64,009 | 41,898 |
| Total operating expenses | 247,839 | 177,063 | 124,388 |
| Loss from operations | (146,817) | (111,443) | (60,916) |
| Other income (expense): | |||
| Gain (loss) on equity investments | 11,825 | (1,781) | 4,108 |
| Change in fair value | (18,084) | 11,359 | 28,263 |
| Other income | 3,950 | 1,057 | 2,253 |
| Total other (expense) income | (2,309) | 10,635 | 34,624 |
| Loss before income taxes | (149,126) | (100,808) | (26,292) |
| Income tax expense | 63 | 411 | 345 |
| Consolidated net loss | (149,189) | (101,219) | (26,637) |
| Net loss attributable to noncontrolling interest | (3) | (826) | (2,174) |
| Net loss attributable to Schrödinger common and limited common stockholders | $ (149,186) | $ (100,393) | $ (24,463) |
| Net loss per share attributable to Schrödinger common and limited common stockholders, basic (in usd per share) | $ (2.10) | $ (1.42) | $ (0.41) |
| Net loss per share attributable to Schrödinger common and limited common stockholders, diluted (in usd per share) | $ (2.10) | $ (1.42) | $ (0.41) |
| Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic (in shares) | 71,173,419 | 70,594,950 | 60,024,658 |
| Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, diluted (in shares) | 71,173,419 | 70,594,950 | 60,024,658 |
| Software products and services | |||
| Revenues: | |||
| Total revenues | $ 135,578 | $ 113,236 | $ 92,530 |
| Cost of revenues: | |||
| Total cost of revenues | 29,576 | 26,495 | 18,003 |
| Drug discovery | |||
| Revenues: | |||
| Total revenues | 45,377 | 24,695 | 15,565 |
| Cost of revenues: | |||
| Total cost of revenues | $ 50,357 | $ 45,816 | $ 26,620 |
SDGR Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 90,474 | $ 120,267 |
| Restricted cash | 5,243 | 3,000 |
| Marketable securities | 360,613 | 456,212 |
| Accounts receivable, net of allowance for doubtful accounts of $125 and $108 | 55,953 | 31,744 |
| Unbilled and other receivables, net for allowance for unbilled receivables of $100 and $30 | 13,137 | 8,807 |
| Prepaid expenses | 8,569 | 5,030 |
| Total current assets | 533,989 | 625,060 |
| Property and equipment, net | 14,244 | 10,025 |
| Equity investments | 25,683 | 43,167 |
| Goodwill | 4,791 | 0 |
| Intangible assets, net | 587 | 0 |
| Right of use assets | 105,982 | 75,384 |
| Other assets | 3,311 | 2,851 |
| Total assets | 688,587 | 756,487 |
| Current liabilities: | ||
| Accounts payable | 9,470 | 8,079 |
| Accrued payroll, taxes, and benefits | 24,882 | 18,405 |
| Deferred revenue | 57,931 | 55,368 |
| Lease liabilities | 11,006 | 2,042 |
| Other accrued liabilities | 5,510 | 7,317 |
| Total current liabilities | 108,799 | 91,211 |
| Deferred revenue, long-term | 25,598 | 30,064 |
| Lease liabilities, long-term | 105,485 | 77,827 |
| Other liabilities, long-term | 800 | 300 |
| Total liabilities | 240,682 | 199,402 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 0 | 0 |
| Additional paid-in capital | 828,700 | 786,964 |
| Accumulated deficit | (379,138) | (229,952) |
| Accumulated other comprehensive loss | (2,382) | (651) |
| Total stockholders’ equity of Schrödinger stockholders | 447,894 | 557,071 |
| Noncontrolling interest | 11 | 14 |
| Total stockholders’ equity | 447,905 | 557,085 |
| Total liabilities and stockholders’ equity | 688,587 | 756,487 |
| Common Stock | ||
| Stockholders’ equity: | ||
| Common stock | 622 | 618 |
| Limited common stock | ||
| Stockholders’ equity: | ||
| Common stock | $ 92 | $ 92 |